Tempest Therapeutics Stock Performance
| TPST Stock | USD 0.95 0.05 5.56% |
Tempest Therapeutics has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 1.84, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tempest Therapeutics will likely underperform. Tempest Therapeutics right now has a risk of 4.69%. Please validate Tempest Therapeutics jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Tempest Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Tempest Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Tempest Therapeutics may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Last Split Factor 1:15 | Dividend Date 2018-12-10 | Last Split Date 2021-06-28 |
1 | Tempest Therapeutics, Inc. Short Interest Update | 11/15/2024 |
2 | Acquisition by Woiwode Thomas of 6635 shares of Tempest Therapeutics at 11.07 subject to Rule 16b-3 | 11/19/2024 |
3 | Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference | 11/25/2024 |
4 | Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 12/06/2024 |
5 | Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com | 12/10/2024 |
6 | Acquisition by Nicholas Maestas of 200000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3 | 01/02/2025 |
7 | Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | 01/06/2025 |
8 | Acquisition by Whiting Samuel of 1700 shares of Tempest Therapeutics at 4.8048 subject to Rule 16b-3 | 01/17/2025 |
| Begin Period Cash Flow | 31.6 M |
Tempest |
Tempest Therapeutics Relative Risk vs. Return Landscape
If you would invest 94.00 in Tempest Therapeutics on November 2, 2024 and sell it today you would earn a total of 1.00 from holding Tempest Therapeutics or generate 1.06% return on investment over 90 days. Tempest Therapeutics is currently generating 0.1239% in daily expected returns and assumes 4.6909% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Tempest, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tempest Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tempest Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tempest Therapeutics, and traders can use it to determine the average amount a Tempest Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0264
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | TPST | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.69 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Tempest Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tempest Therapeutics by adding it to a well-diversified portfolio.
Tempest Therapeutics Fundamentals Growth
Tempest Stock prices reflect investors' perceptions of the future prospects and financial health of Tempest Therapeutics, and Tempest Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tempest Stock performance.
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 36.86 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.60 X | ||||
| EBITDA | (28.78 M) | ||||
| Net Income | (29.49 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 20.66 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | (27.36 M) | ||||
| Earnings Per Share | (1.53) X | ||||
| Market Capitalization | 41.24 M | ||||
| Total Asset | 51.6 M | ||||
| Retained Earnings | (165.26 M) | ||||
| Working Capital | 30.95 M | ||||
About Tempest Therapeutics Performance
Assessing Tempest Therapeutics' fundamental ratios provides investors with valuable insights into Tempest Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tempest Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 408.94 | 429.39 | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (1.27) | (1.33) |
Things to note about Tempest Therapeutics performance evaluation
Checking the ongoing alerts about Tempest Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tempest Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tempest Therapeutics has some characteristics of a very speculative penny stock | |
| Tempest Therapeutics had very high historical volatility over the last 90 days | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (29.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (27.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma |
- Analyzing Tempest Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tempest Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tempest Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tempest Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tempest Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tempest Therapeutics' stock. These opinions can provide insight into Tempest Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.